SI1282402T1 - Stabilizirane vodne suspenzije za parenteralno uporabo - Google Patents

Stabilizirane vodne suspenzije za parenteralno uporabo

Info

Publication number
SI1282402T1
SI1282402T1 SI200130485T SI200130485T SI1282402T1 SI 1282402 T1 SI1282402 T1 SI 1282402T1 SI 200130485 T SI200130485 T SI 200130485T SI 200130485 T SI200130485 T SI 200130485T SI 1282402 T1 SI1282402 T1 SI 1282402T1
Authority
SI
Slovenia
Prior art keywords
aqueous suspensions
parenteral use
stabilized aqueous
stabilized
parenteral
Prior art date
Application number
SI200130485T
Other languages
English (en)
Slovenian (sl)
Inventor
Giuseppe Colombo
Alessandro Martini
Lloyd E Fox
Original Assignee
Pharmacia Italia Spa
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Pharmacia & Upjohn Co Llc filed Critical Pharmacia Italia Spa
Publication of SI1282402T1 publication Critical patent/SI1282402T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200130485T 2000-05-15 2001-04-25 Stabilizirane vodne suspenzije za parenteralno uporabo SI1282402T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use
PCT/EP2001/004643 WO2001087266A1 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use
EP01945040A EP1282402B1 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Publications (1)

Publication Number Publication Date
SI1282402T1 true SI1282402T1 (sl) 2006-04-30

Family

ID=24283530

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130485T SI1282402T1 (sl) 2000-05-15 2001-04-25 Stabilizirane vodne suspenzije za parenteralno uporabo

Country Status (30)

Country Link
US (3) US6495534B2 (OSRAM)
EP (1) EP1282402B1 (OSRAM)
JP (1) JP4205341B2 (OSRAM)
KR (1) KR100828957B1 (OSRAM)
CN (1) CN100473376C (OSRAM)
AR (3) AR029924A1 (OSRAM)
AT (1) ATE313316T1 (OSRAM)
AU (2) AU6737101A (OSRAM)
BR (1) BR0110841A (OSRAM)
CA (1) CA2409059C (OSRAM)
CZ (1) CZ303872B6 (OSRAM)
DE (1) DE60116084T2 (OSRAM)
DK (1) DK1282402T3 (OSRAM)
EA (1) EA007682B1 (OSRAM)
EE (1) EE05376B1 (OSRAM)
ES (1) ES2254443T3 (OSRAM)
HK (1) HK1054194B (OSRAM)
HU (1) HU229800B1 (OSRAM)
IL (2) IL152537A (OSRAM)
IN (1) IN224279B (OSRAM)
MX (1) MXPA02011195A (OSRAM)
NO (1) NO332215B1 (OSRAM)
NZ (1) NZ522324A (OSRAM)
PE (1) PE20011322A1 (OSRAM)
PL (1) PL203075B1 (OSRAM)
SI (1) SI1282402T1 (OSRAM)
SK (1) SK287641B6 (OSRAM)
TW (1) TWI256310B (OSRAM)
WO (1) WO2001087266A1 (OSRAM)
ZA (1) ZA200208738B (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
ATE345277T1 (de) 2002-08-21 2006-12-15 Pharmacia Corp Injizierbare pharmazeutische suspension in einer phiole mit zwei kammern
WO2004043375A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
ATE404175T1 (de) * 2003-03-31 2008-08-15 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
EP1660009B1 (en) 2003-09-03 2015-01-28 Miscon Trading S.A. Methods for the treatment of endometriosis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20060058390A1 (en) * 2004-09-14 2006-03-16 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
US20070191327A1 (en) * 2006-02-15 2007-08-16 Verus Pharmaceuticals, Inc. Sterilization of corticosteroids with reduced mass loss
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
WO2008039473A2 (en) * 2006-09-27 2008-04-03 Scidose Llc Alcohol free formulation of argatroban
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
US9442046B2 (en) 2011-06-19 2016-09-13 Abogen, Inc. Device for sample collection
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9649353B2 (en) 2013-09-17 2017-05-16 Terapio Corporation Methods of preventing or treating mucositis by administering RLIP76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017149492A1 (en) * 2016-03-02 2017-09-08 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
DK3651736T3 (da) 2017-07-14 2021-09-27 Janssen Pharmaceutica Nv Langtidsvirkende formuleringer
EP3678637A1 (en) * 2017-09-07 2020-07-15 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
MX2020002606A (es) * 2017-09-07 2020-10-05 Teva Pharma Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso.
MX2020004792A (es) * 2017-11-08 2020-08-13 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos de su uso.
WO2019140032A1 (en) * 2018-01-11 2019-07-18 Meritage Pharma, Inc. Stable corticosteroid compositions
CA3111901A1 (en) * 2018-09-07 2020-03-12 Prakash SUNDARAMURTHI Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
CA3120708A1 (en) 2018-11-20 2020-05-28 Spectrum Solutions, Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) * 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4277702A1 (en) 2021-01-12 2023-11-22 Durect Corporation Sustained release drug delivery systems and related methods
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
US20240237929A1 (en) * 2021-05-19 2024-07-18 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
ATE99943T1 (de) * 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
KR100408229B1 (ko) 1996-10-04 2003-12-01 암겐 인코포레이티드 Ｍｐｌ 리간드를 함유하는 제약학적 조성물
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
PT1224940E (pt) 1997-09-23 2005-01-31 Rentschler Biotech Gmbh Formulacoes liquidas de intrferao beta
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
EP1067934B1 (en) 1998-04-02 2003-11-26 Akzo Nobel N.V. Oral liquid solution comprising the antidepressant mirtazapine
CA2386228A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
HUP0302021A3 (en) 2011-03-28
ES2254443T3 (es) 2006-06-16
US20030130245A1 (en) 2003-07-10
PL365793A1 (en) 2005-01-10
AU6737101A (en) 2001-11-26
AU2001267371B2 (en) 2006-01-05
HU229800B1 (en) 2014-07-28
KR20030020280A (ko) 2003-03-08
US20020115645A1 (en) 2002-08-22
NO20025431L (no) 2003-01-13
WO2001087266A1 (en) 2001-11-22
BR0110841A (pt) 2003-03-11
SK15982002A3 (sk) 2003-05-02
SK287641B6 (sk) 2011-05-06
CN100473376C (zh) 2009-04-01
US6495534B2 (en) 2002-12-17
DK1282402T3 (da) 2006-05-08
US20030114430A1 (en) 2003-06-19
IL152537A0 (en) 2003-05-29
MXPA02011195A (es) 2003-03-10
EE200200631A (et) 2004-04-15
AR098830A2 (es) 2016-06-15
NZ522324A (en) 2005-02-25
EA200201208A1 (ru) 2003-04-24
JP2003533467A (ja) 2003-11-11
PL203075B1 (pl) 2009-08-31
NO332215B1 (no) 2012-07-30
TWI256310B (en) 2006-06-11
EP1282402B1 (en) 2005-12-21
PE20011322A1 (es) 2002-01-10
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
CA2409059A1 (en) 2001-11-22
CN1429101A (zh) 2003-07-09
AR111695A2 (es) 2019-08-07
EE05376B1 (et) 2011-02-15
HK1054194B (zh) 2010-02-12
CZ303872B6 (cs) 2013-06-05
AR029924A1 (es) 2003-07-23
ZA200208738B (en) 2003-10-29
IN224279B (OSRAM) 2005-02-25
JP4205341B2 (ja) 2009-01-07
CA2409059C (en) 2006-04-18
NO20025431D0 (no) 2002-11-13
ATE313316T1 (de) 2006-01-15
IL165888A0 (en) 2006-01-15
EA007682B1 (ru) 2006-12-29
KR100828957B1 (ko) 2008-05-13
IL152537A (en) 2007-06-17
HK1054194A1 (zh) 2003-11-21
DE60116084T2 (de) 2006-08-17
HUP0302021A2 (hu) 2003-09-29
EP1282402A1 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
AU6737101A (en) Stabilized aqueous suspensions for parenteral use
IL153754A0 (en) Pyrimidine derivatives
HUP0301330A3 (en) 2-aminocarbonyl-9h-purine derivatives
HRP20030055A2 (en) 4-phenyl-pyridine derivatives
IL150841A0 (en) 1h-imidazopyridine derivatives
AU143419S (en) Printer
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
AU143418S (en) Printer
EP1338426A4 (en) PRINTER
HUP0300562A3 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the
IL155705A0 (en) Pyrimidine derivatives
PL356565A1 (en) Aminosulfonylbiphenyl derivatives
GB2371332B (en) Independent suspension
IL150558A0 (en) Aminomethyl-phenyl-cyclohexanone derivatives
TW595555U (en) Suspension
GB2360983B (en) Vehicle suspensions
IL151598A0 (en) 2-phenylpyran-4-one derivatives
GB2359527B (en) Vehicle suspensions
GB0006351D0 (en) Vehicle suspensions
PL342463A1 (en) Aqueous filter
TW444660U (en) Suspension clip
CA93294S (en) Paper holder
GB0004490D0 (en) Vehicle suspensions
CA90959S (en) Notepad holder
SI1303496T1 (sl) Pirimidinski derivati